Policy / Pricing Pharma’s Reluctance To Serve Europe To Dodge MFN Drug Pricing Is Chilling BioSpaceAs Big Pharma companies consider foregoing European drug launches to avoid reducing drug prices in the U.S.Policy / PricingRead full story pharminent April 2, 2026 (Last updated: April 2, 2026) BioSpace As Big Pharma companies consider foregoing European drug launches to avoid reducing drug prices in the U.S. Policy / PricingRead full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Pfizer, BioNTech Halt Large US COVID-19 Vaccine Trial Over Slow EnrollmentNext: ACC 2026: sotatercept meta-analysis backs disease-modifying role in PAH Related Stories Policy / Pricing US generic tariff reprieve on the rocks as Trump proposes 100% rate in 2028 pharminent July 22, 2026 Policy / Pricing UK commits to pharma IP protection in Swiss trade deal pharminent July 16, 2026 Policy / Pricing Germany approves healthcare costs overhaul despite significant pharma opposition pharminent July 13, 2026
